TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. (TMDX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 63.58 M | 121.13 M | 568.85 M | 706.05 M | 510.65 M |
| 2022 | 27.61 M | -133,627,000 | 89.77 M | 277.15 M | 252.29 M |
| 2021 | 5.93 M | -16,976,000 | 67.04 M | 134.89 M | 118.71 M |
| 2020 | 6.86 M | 10.08 M | 48.14 M | 152.03 M | 146.77 M |
| 2019 | 6.56 M | 14.05 M | 50.65 M | 105.3 M | 100 M |